# Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

> **NCT00690820** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Cystic Fibrosis
- Pancreatic Exocrine Insufficiency

## Interventions

- **DRUG:** Pancrelipase Delayed Release
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT00690820
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2010-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00690820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00690820, "Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00690820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*